Author

Yun Liao

Coriell Institute For Medical ResearchORCID 0000-0002-8151-8885Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Anthony PompettiiD· 2 shared Dan Yang· 2 shared Dongwook Kim· 2 shared Gennaro CalendoiD· 2 shared Jian Yuan HuangiD· 2 shared Srinivas ChatlaiD· 2 shared Xiaoyu WeiiD· 2 shared Zhen TianiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anthony PompettiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia

Zhen Tian, Xiaoyu Wei, Srinivas Chatla, Yang Liu, Dongwook Kim, Yahui Li, Peng Wang, Yun Liao, Xiaolei Liu, Dan Yang, Stacia Octaviani, Gui Ma, Anthony Pompetti, Gennaro Calendo, Martin P. Keough, , Jian Yuan Huang

This paper identifies RNR inhibition as a strategy to overcome FLT3 inhibitor resistance in FLT3ITD+ AML by reversing resistance mechanisms and enhancing therapeutic efficacy.

bioRxiv · Jul 22, 2026 · PreprintCancer Biology

Targeting Cellular Pseudo-Senescence to Overcome PARP inhibitors Resistance in BRCA1 -Mutated Breast Cancer

Zhen Tian, Srinivas Chatla, Shreya Indulkar, Dongwook Kim, Xiaoyu Wei, Yun Liao, Dan Yang, Anthony Pompetti, Gennaro Calendo, Congli Wang, Tina Bocker Edmonston, Zhenkun Lou, Tomasz Skórski, Liewei Wang, Jian Yuan Huang

This study identifies ZNF251 deficiency as a driver of PARP inhibitor resistance in BRCA1-mutant breast cancer, showing that targeting pseudo-senescence with senomorphic or senolytic therapies can overcome resistance.

bioRxiv · Jun 26, 2026 · PreprintCancer Biology